From the Journals

MS plus depression can increase risk of death, vascular disease


 

FROM NEUROLOGY

Evaluating the biological interaction between MS and depression

Based on this and other studies, the joint effect of MS and depression on all-cause mortality may qualify as a biological interaction, Amber Salter, PhD, of the University of Texas Southwestern Medical Center, Dallas, wrote in an accompanying editorial.

“Biological interactions consider whether the joint effect of two factors follow an additive pattern, or the joint effect of two factors is greater than the sum of the individual effects for each factor alone,” she wrote. And though the interaction was not found to be present for vascular disease and cardiovascular mortality, it was for all-cause mortality.

“When warranted, the evaluation of biological interactions in future studies should be considered to provide insight on target subpopulations for interventions or test for potential mechanistic forms of interaction,” she added.

Dr. Salter highlighted the study’s strengths, including a large sample size and six controls matched to each MS patient. She also stated that the researchers’ inability to control for risk factors like body mass index and physical activity means the 14% increase in mortality “may not be a large absolute increase in mortality when other covariates cannot be considered.” In addition, their lack of data on suicide – and its association with depression – offers up the possibility that increases in mortality could be tied to a “potentially modifiable risk” as opposed to a biologically increased one.

In acknowledging their study’s limitations, the authors stated that body mass index, though an important vascular risk factor, has a “modest” association with mortality, and that the average annual suicide rate in the MS population – though higher than in the non-MS population – is still “relatively low.”

Two of the authors disclosed receiving support, including grants and research funding, from various institutions and organizations in the United Kingdom, the United States, and Canada, as well as several pharmaceutical companies. Dr. Salter reported no relevant disclosures.

Pages

Recommended Reading

Some MS treatments may heighten COVID risk
MDedge Neurology
Investigational drug reduces brain lesions in highly active MS
MDedge Neurology
Multiple sclerosis updates from AAN 2021
MDedge Neurology
A less expensive, more convenient treatment option for MS?
MDedge Neurology
MS CONFERENCE NEWS
MDedge Neurology
MS CONFERENCE NEWS
MDedge Neurology
Guidance on additional COVID-19 vaccine dose for MS patients
MDedge Neurology
Progressive disability in MS explained?
MDedge Neurology
NIH to study COVID vaccine booster in people with autoimmune disease
MDedge Neurology
MRI is a poor disability predictor in secondary progressive MS
MDedge Neurology